825 Spam-Free Article(s) Found
Sort:
Like
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
MRK Merck & Company, Inc. $70.42 $187.28B Downtrend
Article Searches
Merck's Keytruda Plays Catch-Up to Bristol-Myers' Opdivo https://www.fool.com/investing/2017/08/01/mercks-keytruda-plays-catch-up-to-bristol-myers-op.aspx?source=iedfolrf0000001 Aug 02, 2017 - The two biopharma giants PD-1 inhibitors are facing off against each other in cancer indications that are worth billions of dollars in annual sales.
4 of the Highest-Growth Stocks in Biotech Today https://www.fool.com/investing/2017/08/24/4-of-the-highest-growth-stocks-in-biotech-today.aspx?source=iedfolrf0000001 Aug 24, 2017 - How does a compound annual growth rate of 50%, 60%, or 70% sound?
Immune Design (IMDZ): Stock to Disappoint on Q2 Earnings? http://www.zacks.com/stock/news/226941/immune-design-imdz-stock-to-disappoint-on-q2-earnings?cid=CS-ZC-FT-226941 Aug 04, 2016 - Immune Design Corp. (IMDZ) is scheduled to report second-quarter 2016 results after the market closes on Aug 9.
Bristol-Myers (BMY) Collaborates with Apexigen for Opdivo http://www.zacks.com/stock/news/256261/bristol-myers-bmy-collaborates-with-apexigen-for-opdivo?cid=CS-ZC-FT-256261 Apr 12, 2017 - Bristol-Myers Squibb Company (BMY) announced a collaboration agreement with clinical-stage biopharmaceutical company Apexigen, Inc.
Merck & Co. Inc.: The Bear Case from a Bull https://www.fool.com/investing/2017/06/29/merck-co-inc-the-bear-case-from-a-bull.aspx?source=iedfolrf0000001 Jun 29, 2017 - A pessimistic look at Merck from an optimist.
Pharma Stock Roundup: Mylan, Endo Report 4Q Results, FDA Nod for AZN Diabetes Drug http://www.zacks.com/stock/news/251551/pharma-stock-roundup-mylan-endo-report-4q-results-fda-nod-for-azn-diabetes-drug?cid=CS-ZC-FT-251551 Mar 03, 2017 - Quite a few companies including AstraZeneca (AZN) provided pipeline/regulatory updates this week.
Merck's (MRK) Management Presents at Investor Briefing at 2017 ASCO Annual Meeting Conference (Transcript) https://seekingalpha.com/article/4079009-mercks-mrk-management-presents-investor-briefing-2017-asco-annual-meeting-conference?source=feed_all_articles Jun 06, 2017 - Merck & Co Inc. (NYSE:MRK) Investor Briefing at 2017 ASCO Annual Meeting Call June 5, 2017 18:45 ET Executives Teri Loxam - Investor Relations Roger Perlmutter - President, Merck Research Labs Fra
3 Top High-Yield Pharmaceutical Stocks to Buy Now https://www.fool.com/investing/2017/07/03/3-top-high-yield-pharmaceutical-stocks-to-buy-now.aspx?source=iedfolrf0000001 Jul 03, 2017 - AstraZeneca, GlaxoSmithKline, and Teva Pharmaceutical Industries sport some of the highest dividend yields among drugmakers today. Here's why their rewards could outweigh their risks.
The Top Cancer Immunotherapies Expected to Reach $1 Billion in Sales in 2017 https://www.fool.com/investing/2017/09/18/the-top-cancer-immunotherapies-expected-to-reach-1.aspx?source=iedfolrf0000001 Sep 18, 2017 - These next-generation medicines are quickly becoming the foundation for advanced cancer treatments.
3 Top Stocks That Aren't on Wall Street's Radar https://www.fool.com/investing/2018/07/15/3-top-stocks-that-arent-on-wall-streets-radar.aspx?source=iedfolrf0000001 Jul 15, 2018 - You can buy these three surprising companies before Wall Street catches on. It could pay off with huge returns, too.

Pages: 123456789...83

<<<Page 4>